BOUNDLESS BIO, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | $-58.2M | $-65.4M | $-49.4M |
| Depreciation & Amortization | $1.3M | $1.1M | $957.0K |
| Depreciation | — | — | — |
| Amortization | — | — | — |
| Stock-Based Compensation | $6.1M | $7.5M | $3.3M |
| Net Cash from Operating Activities | $-46.7M | $-60.8M | $-46.9M |
| Investing Activities | |||
| Capital Expenditures | $546.0K | $2.5M | $633.0K |
| Business Acquisitions | — | — | — |
| Net Cash from Investing Activities | $37.8M | $-26.1M | $-38.3M |
| Financing Activities | |||
| Dividends Paid | — | — | — |
| Stock Repurchases | — | — | — |
| Net Cash from Financing Activities | $141.0K | $89.8M | $97.9M |
| Net Change in Cash | $-8.7M | $2.9M | $12.8M |
| Free Cash Flow | $-47.2M | $-63.4M | $-47.5M |